Tirzepatide Beats Dulaglutide on Cardiorenal Outcomes in Real-World HFpEF
This propensity-matched TriNetX cohort offers the first real-world head-to-head of two incretin agents in heart failure with preserved ejection fraction (HFpEF), suggesting a hierarchy within the GLP-1 class that is relevant to formulary and selection decisions.
📅 Journal publication: Aug 2026·Last updated: Oct 5, 2026
Tirzepatide outperforms dulaglutide in cardiorenal protection for HFpEF.
Comparing the efficacy of tirzepatide and dulaglutide in heart failure with preserved ejection fraction (HFpEF) provides insights into optimal treatment for reducing cardiac and renal risks. Tirzepatide showed lower 1-year risks of mortality (HR: 0.66), hospitalization (HR: 0.85), stroke (HR: 0.92), major adverse cardiac events (MACE) (HR: 0.89), and major adverse kidney events (MAKE) (HR: 0.85) compared to dulaglutide. Tirzepatide presents as a preferable option for HFpEF patients, offering significant benefits in mortality and cardiorenal outcomes over dulaglutide in a real-world setting. Tirzepatide markedly improves long-term cardiorenal outcomes in HFpEF over dulaglutide.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Khalil I, Hossain MI, Akter MM, Wahid F, Khalid AA, Promi SA, Sayed MA, Rahman MT, Sarker P
Citation:Khalil I, Hossain MI, Akter MM, et al. Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis. Clinical cardiology. 2026;49(8):e70441. doi:10.1002/clc.70441